@conference{
author = "Mitrović, Jelena and Divović, Branka and Dobričić, Vladimir and Čalija, Bojan and Vulić, Jelena P. and Knutson, Daniel E. and Cook, James M. and Savić, Miroslav and Savić, Snežana",
year = "2019",
abstract = "Deuterated pyrazoloquinolinones, GABAn receptor ligands, are being investigated for neuropsychiatric disorders treatment. Among others, DK-l-56-1 (7-Methoxy-2-(4-methoxy-d3- p h e n yl ) - 2, 5 -d i h yd ro - 3 H - py r azolo -14,3 -clq u i n o I i n - 3-one) was chosen as the lead component [1]. Because of its low solubility in water (6.27 t0.74 pg/ml) nanosuspension formulation for prospective parenteral administration was carried out [2]. ...",
journal = "10th International Congress Nanotechnology in Medicine & Biology, 15 - 17. April 2019, Graz / Austria",
title = "Nanonization of new patent protected substances - carrier selection for preclinical research: physicochemical and in vivo behavioral characterization",
url = "https://hdl.handle.net/21.15107/rcub_farfar_5542"
}